VivoSim Labs (VIVS) Income from Continuing Operations (2010 - 2026)
VivoSim Labs (VIVS) posted quarterly Income from Continuing Operations of 3155000.0 for Q1 2026, down 19.73% year-over-year from 3930697.4 in Q1 2025, and down 9.36% quarter-over-quarter from 2885000.0 in Q4 2025.
VivoSim Labs (VIVS) Income from Continuing Operations (2010 - 2026) Analysis & Trends
VivoSim Labs' Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 3155000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 19.73% year-over-year to 3155000.0; the TTM figure through Mar 2026 stood at 11692000.0 (up 5.84% YoY), while the FY2026 annual figure was 14219000.0, up 6.97% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 3155000.0, down from 2885000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 2094000.0 in Q1 2022, with the low at 7454000.0 in Q1 2023.
- The 5-year median for Income from Continuing Operations is 3275000.0 (2022), against an average of 3445705.88.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations sank 255.97% in 2023, then jumped 62.14% in 2024.
- VivoSim Labs' Income from Continuing Operations stood at 3275000.0 in 2022, then dropped by 13.86% to 3729000.0 in 2023, then gained by 4.24% to 3571000.0 in 2024, then increased by 19.21% to 2885000.0 in 2025, then fell by 9.36% to 3155000.0 in 2026.
- Business Quant data shows VIVS's Income from Continuing Operations at 3155000.0 in Q1 2026, 2885000.0 in Q4 2025, and 2679000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | VivoSim Labs | 1.49 Mn | 1.49 Mn | - | -2.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.06 Mn |
| Mar 31, 2026 | -3.16 Mn |
| Dec 31, 2025 | -2.89 Mn |
| Sep 30, 2025 | -2.68 Mn |
| Jun 30, 2025 | -2.97 Mn |
| Mar 31, 2025 | -2.64 Mn |
| Dec 31, 2024 | -3.57 Mn |
| Sep 30, 2024 | -2.74 Mn |
| Jun 30, 2024 | -3.47 Mn |
| Mar 31, 2024 | -2.82 Mn |
| Dec 31, 2023 | -3.73 Mn |
| Sep 30, 2023 | -4.12 Mn |
| Jun 30, 2023 | -4.17 Mn |
| Mar 31, 2023 | -7.45 Mn |
| Dec 31, 2022 | -3.28 Mn |
| Sep 30, 2022 | -3.48 Mn |
| Jun 30, 2022 | -3.33 Mn |
| Mar 31, 2022 | -2.09 Mn |
| Dec 31, 2021 | -4.03 Mn |
| Sep 30, 2021 | -3.51 Mn |